Zoledronic acid 5 mg/100 mL bottle; solution for IV infusion. Paget’s disease of bone is characterized by greatly increased and disorderly bone remodeling. Excessive osteoclastic bone resorption is ...

The FDA has approved Reclast (zoledronic acid injection, from Novartis) for the prevention of new clinical fractures in patients who have recently had a low-trauma hip fracture. The approval was based ...

Reclast (zoledronic acid) is a medication that the Food and Drug Administration (FDA) has approved for preventing and treating osteoporosis in females after menopause, males, and individuals who take ...

An experimental treatment for bone-thinning osteoporosis appears to prevent spine and hip fractures even though it is given only once a year, eliminating the need for a strict daily pill regimen, ...

Approval is reportedly the first to allow dosing every two years. FDA approved Novartis’ Reclast(r) as the first two-yearly treatment for the prevention of postmenopausal osteoporosis. The agency ...

Sept 1 (Reuters) - U.S. health regulators on Thursday approved a label update to Novartis AG's osteoporosis drug Reclast to warn about the risk of kidney failure associated with the use of the drug.

Dear Dr. Roach: For the last few years, I have been taking yearly Reclast infusions for osteoporosis, because I have trouble taking oral medications of any kind. The infusion was given in February ...

Data to be published in this week’s issue of The New England Journal of Medicine show that a once-yearly treatment significantly reduced the incidence of all types of osteoporotic bone fractures over ...

*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Dear Dr. Roach: For the last few years, I have been taking yearly Reclast infusions for osteoporosis, because I have trouble ...